Andrew Reardon - 29 Dec 2023 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
CHIEF LEGAL OFFICER &
Signature
/s/ Andrew Reardon
Issuer symbol
LGND
Transactions as of
29 Dec 2023
Net transactions value
+$10,867
Form type
4
Filing time
04 Jan 2024, 16:07:14 UTC
Previous filing
14 Aug 2023
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Other $10,867 +179 +1.2% $60.71 15,590 29 Dec 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c).